COPD affects an estimated 400 million people worldwide.1
Key highlights:
In COPD, the airways become inflamed and damaged, which leads to obstructed and restricted airflow.2,3
Evidence suggests that up to 66% of COPD patients may exhibit a Type 2 inflammation.9
FeNO testing offers a simple, convenient and non-invasive method for identifying Type 2 high patients.
What is COPD?
Chronic obstructive pulmonary disease (COPD) is an umbrella term for several chronic obstructive lung conditions, including emphysema and chronic bronchitis, and it affects more than 400 million patients worldwide.1,2 In COPD, the airways become inflamed and damaged, which leads to obstructed, restricted airflow – making it harder to breathe.2,3
COPD is often linked to long-term exposure to inhaling harmful substances, such as cigarette smoking, which is responsible for almost 90% of cases, and occupational exposures including silica dust, welding fumes and cleaning products.2,3 Typical symptoms include shortness of breath, wheezing, persistent chesty cough and frequent chest infections.2
The challenge of COPD
COPD is a progressive disease and cannot be cured, however, treatment and lifestyle changes can help to slow down the progression.2,3 COPD exacerbations are not uncommon, often being triggered by respiratory infections.4
3rd leading cause of death worldwide5
Affects 10.6% of the population5
Smoking is responsible for around 90% of COPD cases2
Why measure FeNO for COPD?
While FeNO is typically associated with asthma, it’s role in COPD is gaining interest as a biomarker for Type 2 airway inflammation which is often recognised as a “treatable trait” that can help support a more personalised approach to care.6,7
COPD is heterogeneous disease, and it is not uncommon for patients to show positive Type 2 inflammatory biomarkers.7 The two main COPD endotypes are Type 2 eosinophilic phenotype, and the neutrophilic phenotype, with evidence suggesting that up to 66% of COPD patients may exhibit a Type 2 inflammatory profile.8,9
FeNO testing offers a simple, practical and non-invasive method for identifying Type 2 high COPD patients.7,11 By detecting Type 2 airway inflammation, FeNO can help to assess patients’ risk, guide treatment decisions, and predict clinical outcomes in COPD.8,11
Why measure FeNO?
FeNO is the convenient way to assess airway inflammation at the point-of-care12
Simple
One test, one number. Airway inflammation in a single FeNO level.
Immediate
Performing a FeNO test takes approximately one minute - quicker than making a cup of coffee.
Non-invasive
Taking a FeNO test is as simple as inhaling and exhaling: no blood, sweat or tears required.
